ID3 enhances intrahepatic cholangiocarcinoma (ICC) stemness by increasing β‐catenin transcriptional activity, indicating its potential as a biomarker for predicting ICC patient responses to adjuvant chemotherapy.9 Here, ID3 is linked to intrahepatic cholangiocarcinoma.